RxDoctor Payments Data

Terry Brown, MD

Internal Medicine · Stillwater, OKNPI 1124004759

Payments from drug & device makers

$2,348in general payments, 2019–2025

Across 159 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$362
  • AstraZeneca$308
  • Pfizer$301
  • Abbott$188
  • Amarin Pharma, Inc.$188
  • Boehringer Ingelheim$180
  • plus $822 from 19 others

What the payments were for

  • Food & beverage$2,336100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,348 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$146,321
Medicare patients
514
Services billed
2,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$95,280
JardianceEmpagliflozin93$80,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$67,757
TrulicityDulaglutide41$50,512
MounjaroTirzepatide28$31,250
OzempicSemaglutide23$30,222
XareltoRivaroxaban21$28,081
Spiriva RespimatTiotropium Bromide29$18,621
Spiriva HandihalerTiotropium Bromide16$11,744
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$9,067
TrintellixVortioxetine Hydrobromide12$6,154
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$6,100
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$5,884
Atorvastatin Calcium488$5,597
Incruse ElliptaUmeclidinium Bromide16$5,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$180$99,465122 claims
PfizerEliquis, Paxlovid$301$98,138140 claims
Lilly USA, LLCTrulicity, Mounjaro$362$81,76269 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$149$78,855118 claims
Novo NordiskOzempic$64$30,22223 claims
Johnson & JohnsonXarelto$37$28,08121 claims
AstraZenecaBevespi Aerosphere$308$5,88413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Stillwater

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →